As of close of business last night, BioNTech SE ADR’s stock clocked out at $90.00, down -4.38% from its previous closing price of $94.12. In other words, the price has decreased by -$4.12 from its previous closing price. On the day, 2941115 shares were traded.
Ratios:
To gain a deeper understanding of BNTX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.50 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.45. For the most recent quarter (mrq), Quick Ratio is recorded 10.14 and its Current Ratio is at 10.37. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on February 23, 2024, initiated with a Outperform rating and assigned the stock a target price of $127.
JP Morgan Downgraded its Neutral to Underweight on December 01, 2023, whereas the target price for the stock was revised from $106 to $99.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNTX now has a Market Capitalization of 21.40B and an Enterprise Value of 3.64B. As of this moment, BioNTech’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.82, and their Forward P/E ratio for the next fiscal year is 133.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.10 while its Price-to-Book (P/B) ratio in mrq is 1.02. Its current Enterprise Value per Revenue stands at 0.55 whereas that against EBITDA is 0.95.
Stock Price History:
Over the past 52 weeks, BNTX has reached a high of $136.91, while it has fallen to a 52-week low of $87.90. The 50-Day Moving Average of the stock is 94.84, while the 200-Day Moving Average is calculated to be 103.43.
Shares Statistics:
It appears that BNTX traded 653.57K shares on average per day over the past three months and 813.69k shares per day over the past ten days. A total of 243.22M shares are outstanding, with a floating share count of 237.70M. Insiders hold about 0.01% of the company’s shares, while institutions hold 17.84% stake in the company. Shares short for BNTX as of Feb 29, 2024 were 2.92M with a Short Ratio of 4.47, compared to 3.02M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.23% and a Short% of Float of 3.52%.
Earnings Estimates
As of right now, 12 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $2.63 for the current quarter, with a high estimate of $3.82 and a low estimate of $0.87, while EPS last year was $9.93. The consensus estimate for the next quarter is -$0.43, with high estimates of $1.52 and low estimates of -$2.07.
Analysts are recommending an EPS of between $10.87 and $2.98 for the fiscal current year, implying an average EPS of $5.08. EPS for the following year is $0.68, with 16 analysts recommending between $6.44 and -$4.19.
Revenue Estimates
In the current quarter, 11 analysts expect revenue to total $1.99B. It ranges from a high estimate of $3.08B to a low estimate of $1.58B. As of the current estimate, BioNTech SE ADR’s year-ago sales were $4.58B, an estimated decrease of -56.60% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $713.17M, a decrease of -49.10% over than the figure of -$56.60% in the same quarter last year. There is a high estimate of $1.37B for the next quarter, whereas the lowest estimate is $306.73M.
A total of 18 analysts have provided revenue estimates for BNTX’s current fiscal year. The highest revenue estimate was $6.02B, while the lowest revenue estimate was $4.28B, resulting in an average revenue estimate of $4.66B. In the same quarter a year ago, actual revenue was $18.56B, down -74.90% from the average estimate. Based on 19 analysts’ estimates, the company’s revenue will be $3.43B in the next fiscal year. The high estimate is $5.42B and the low estimate is $2.34B. The average revenue growth estimate for next year is down -26.40% from the average revenue estimate for this year.
